Grünenthal Press Releases 2016
Welcome to Grünenthal's Press Overview
23 Jun 2016
Aachen/Brussels, 23 June 2016. For the tenth time, young European scientists who have an innovative pain research idea, are called upon to apply for one of the most prestigious and highly regarded pain research grants worldwide: The EFIC-GRÜNENTHAL Grant (E-G-G).
07 Jun 2016
Grünenthal appoints Gabriel Baertschi as Chairman of the Corporate Executive Board and Chief Executive Officer effective October 1, 2016
Swiss native Gabriel Baertschi follows Prof. Dr. Eric-Paul Pâques who retires after 23 years with the company
Grünenthal Group today announced that its Supervisory Board has named Gabriel Baertschi to become Grünenthal’s new CEO as of October 1, 2016. Gabriel Baertschi will join Grünenthal from AstraZeneca, a global, science-led biopharmaceutical business where he currently serves as country president for Japan. He succeeds Prof. Dr. Eric-Paul Pâques, who has been the CEO of the Grünenthal Group. Grünenthal is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany with affiliates in Europe, Latin America and the U.S. In 2015, Grünenthal achieved revenues of € 1.2 bn.
02 Jun 2016
Aachen, June 2, 2016. Grünenthal Group today announced that it has entered into a licensing agreement with AstraZeneca for the exclusive rights to Zurampic™ (lesinurad) in Europe and Latin America. Zurampic™ was approved by the European Medicines Agency (EMA) in February 2016, in combination with a xanthine oxidase inhibitor (XOI), for the treatment of adjunctive hyperuricemia in adult patients with uncontrolled gout.
11 May 2016
Grünenthal announces exclusive license agreement for commercialization of innovative surgical glue in the EU and Latin America
Agreement underpins Grünenthal’s strategy to strengthen its portfolio for the European hospital market
The Grünenthal Group today announced an exclusive license and supply agreement with Adhesys Medical Inc., USA, on the commercialization of an innovative topical skin adhesive. With this agreement, Grünenthal acquires the exclusive distribution rights for the EU and Latin American markets. Both companies pursue the common objective to launch a medical device that meets highest standards.
15 Mar 2016
Aachen, Germany and Mexico City, Mexico, March 15, 2016. Grünenthal Group announced today to have entered into a definitive agreement with Almirall Group under which Grünenthal will acquire 100% of the share capital of Almirall de Mexico. The transaction also includes an agreement to perpetually license a portfolio of mainly international products with around 17.5 million Euro net sales in 2015 in Mexico. The transaction will be completed in early May, 2016.
03 Mar 2016
Grünenthal capitalizes on Axxam’s drug discovery platform and expertise to identify small molecule lead structures for its early pipeline in pain and inflammation
Grünenthal and Axxam announced today that they have entered into an integrated collaboration. The objective is to discover novel small molecule lead structures for the development of pain and inflammation therapeutics by combining Axxam’s drug discovery platform with Grünenthal’s expertise on emerging and innovative biological pathways and targets.
22 Feb 2016
PATHEON SELECTED BY GRÜNENTHAL TO DEVELOP DRUGS USING INTAC® ABUSE DETERRENT FORMULATIONS TECHNOLOGY
Patheon, the leading global provider of pharmaceutical development and manufacturing services today announced it has signed a strategic agreement with Grünenthal, an independent, family-owned, international research-based pharmaceutical group headquartered in Aachen, Germany to serve as its preferred development partner for its products made using Grünenthal’s innovative abuse deterrent formulation technology INTAC®.
10 Feb 2016
Inauguration of new research building on Grünenthal Campus in Aachen
The Grünenthal Group announced today the completion and inauguration of its new research building on the Grünenthal Campus in Aachen. It will accommodate room for 150 employees working in research and development. Thus Grünenthal again commits to its headquarters in Aachen and to researching and developing of innovative medicines to the benefits of patients. The annual Research & Development expenditures of the group have constantly been well above the pharmaceutical industry’s average for years in relation to sales. The Grünenthal Campus in Aachen has been continuously enlarged since 2011. In the last five years, the company has invested 131 million Euros for real estate, buildings and production sites.
08 Jan 2016
Grünenthal and Akashi Therapeutics Inc. announce joint drug development program for HT-100 in the treatment of patients with Duchenne Muscular Dystrophy (DMD)
- HT-100 is an orally available small molecule drug candidate designed to reduce fibrosis and inflammation and to promote healthy muscle fiber regeneration in patients with DMD
- DMD is a rare, yet the most common fatal genetic disorder diagnosed in childhood. Today, no curative treatment exists, and patients typically die in their twenties
06 Jan 2016
Grünenthal's Innovative Medicines Unit (IMU) opens its first Innovation Hub to further strengthen the company’s networked Research and Development approach
- The IMU – Leiden Hub will serve as Grünenthal’s European center for Open Innovation
- Integration in scientific community of Leiden Bio Science Park, the Netherlands, enables easier access and close collaboration with leading scientists and institutions
- At Leiden Bio Science Park, about 17,000 employees in biomedical companies, research institutions and hospitals are dedicated to the development of innovative drugs and solutions to support patients